Actively Recruiting
TIRANA-ACS: Prospective Registry for Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome
Led by University Hospital Centre Mother Teresa · Updated on 2025-09-30
1600
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
Sponsors
U
University Hospital Centre Mother Teresa
Lead Sponsor
C
Charite University, Berlin, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the role of the neutrophil-to-lymphocyte ratio (NLR) as a predictor of mortality in patients who have had an episode of Acute Coronary Syndrome (ACS). This observational study focuses on patients admitted with a confirmed diagnosis of ACS, including STEMI and Non-STEMI, who are treated with percutaneous coronary intervention (PCI). The study aims to determine if NLR, a simple and cost-effective blood test marker, can help predict death and major heart events within six months after ACS, improving early risk assessment and patient outcomes. Participants will have their NLR measured from blood samples taken at hospital admission, then again at 24 and 48 hours after PCI. The study will collect detailed clinical data including patient information, angiography results, and various blood markers like C-reactive protein and troponin levels. Follow-up will occur through telephone interviews up to six months after discharge, using standardized questionnaires to assess patient health and symptoms. During the study, patients' health status will be evaluated at 24 hours, 48 hours, and six months after symptom onset. Researchers will monitor mortality rates, major adverse cardiac events, and associations of NLR with other clinical factors. This comprehensive approach includes gathering clinical records, laboratory results, and patient-reported outcomes to better understand NLR's value in predicting post-ACS risks and potentially guiding future care strategies.
CONDITIONS
Brief Title
TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 85 years
- Undergoing PCI
- Diagnosed with Acute Coronary Syndrome (ACS)
- Admitted to the cardiology department or intensive care unit
You will not qualify if you...
- Patients diagnosed with conditions other than ACS or unstable angina
- Patients who died before undergoing PCI
- Patients who did not provide a contact number
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within first 5 days of admission
Participants undergo coronary angiography and hospital assessments to collect diagnostic and inflammatory marker data.
Hospital visits during initial admission
Duration - 6 months with potential extension up to 12 months
Participants are observed and their health status is evaluated at several time points after symptom onset.
3 assessments at 24 hours, 48 hours, and 6 months post-symptom onset; telephone interviews for follow-up
Trial Site Locations
Total: 1 location
1
Faculty of Medicine Tirana
Tirana, Albania, 1005
Actively Recruiting
Research Team
M
Martiola Kola, MD
A
Andi Rroku, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here